Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GENETIC-AF
2016-000302-12Phase 2Completed
- Sponsor
- Oruka Therapeutics
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Atrial fibrillation (AFib), atrial flutter (AFL) and heart failure with reduced ejection fraction (HFrEF) comparing Bucindolol arm with Toprol-XL arm (2 arms). Primary endpoints: Time to first symptomatic AF/AFL recurrence or all-cause mortality, Time to first symptomatic AF/AFL recurrence and 1 more. Started May 2016; status: completed.
02
Drugs
bucindololmetoprolol
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2016-000302-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000302-12.